Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,140 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Tojima H, Shimada Y, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: nagashima t. Hepatol Res. 2020 Mar;50(3):382-395. doi: 10.1111/hepr.13460. Epub 2019 Dec 10. Hepatol Res. 2020. PMID: 31760660
A change in the timing for starting systemic therapies for hepatocellular carcinoma: the comparison of sorafenib and lenvatinib as the first-line treatment.
Hatanaka T, Kakizaki S, Nagashima T, Ueno T, Namikawa M, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: nagashima t. Acta Gastroenterol Belg. 2021 Jan-Mar;84(1):65-72. doi: 10.51821/84.1.109. Acta Gastroenterol Belg. 2021. PMID: 33639695 Free article.
Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T, Kakizaki S, Uehara D, Nagashima T, Ueno T, Namikawa M, Saito S, Hosonuma K, Suzuki H, Naganuma A, Takagi H, Sato K, Uraoka T. Hatanaka T, et al. Among authors: nagashima t. Intern Med. 2019 Jul 1;58(13):1835-1844. doi: 10.2169/internalmedicine.1594-18. Epub 2019 Mar 28. Intern Med. 2019. PMID: 30918170 Free PMC article.
Favorable outcome of retreatment by direct-acting antivirals for hepatitis C patients with daclatasvir plus asunaprevir combination therapy failure.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: nagashima t. Hepatol Res. 2020 Mar;50(3):303-312. doi: 10.1111/hepr.13462. Epub 2019 Dec 19. Hepatol Res. 2020. PMID: 31750974
Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment.
Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: nagashima t. Cancers (Basel). 2020 Oct 10;12(10):2906. doi: 10.3390/cancers12102906. Cancers (Basel). 2020. PMID: 33050527 Free PMC article.
The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study.
Hatanaka T, Naganuma A, Shibasaki M, Kohga T, Arai Y, Nagashima T, Ueno T, Namikawa M, Saito S, Hoshino T, Takizawa D, Arai H, Makita F, Kakizaki S, Harimoto N, Shirabe K, Uraoka T. Hatanaka T, et al. Among authors: nagashima t. Oncology. 2021;99(4):203-214. doi: 10.1159/000511734. Epub 2020 Dec 4. Oncology. 2021. PMID: 33279908
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Hiraoka A, et al. Among authors: nagashima t. Hepatol Res. 2021 Aug;51(8):880-889. doi: 10.1111/hepr.13644. Epub 2021 May 5. Hepatol Res. 2021. PMID: 33837620
Elevated serum uric acid level was a notable adverse event during combination therapy with sofosbuvir and ribavirin.
Sato K, Naganuma A, Nagashima T, Hoshino T, Uehara D, Arai Y, Horiuchi K, Yuasa K, Takayama H, Arai H, Hatanaka T, Ohyama T, Tahara H, Sohara N, Kobayashi T, Horiguchi N, Yamazaki Y, Kakizaki S, Kusano M, Yamada M, Murase T, Nakamura T. Sato K, et al. Among authors: nagashima t. Hepatol Res. 2018 Feb;48(3):E347-E353. doi: 10.1111/hepr.12971. Epub 2017 Sep 25. Hepatol Res. 2018. PMID: 28834004
Follow-up after Direct-acting Antiviral Treatment for Chronic Hepatitis C Virus Infection: Most Patients Are Followed Appropriately.
Tojima H, Kakizaki S, Takakusagi S, Hoshino T, Naganuma A, Nagashima T, Namikawa M, Ueno T, Shimada Y, Hatanaka T, Takizawa D, Arai H, Sato K, Takagi H, Uraoka T. Tojima H, et al. Among authors: nagashima t. Intern Med. 2021;60(19):3061-3070. doi: 10.2169/internalmedicine.6591-20. Epub 2021 Oct 1. Intern Med. 2021. PMID: 34602520 Free PMC article.
1,140 results